CellBion Co., Ltd. (KOSDAQ:308430)

South Korea · Delayed Price · Currency is KRW

14,310

+350 (2.51%)

At close: Oct 1, 2026

Market Cap	184.67B -19.5%
Revenue (ttm)	2.15B -18.4%
Net Income	7.75B
EPS	590.89
Shares Out	12.91M
PE Ratio	24.22
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,309
Open	13,960
Previous Close	13,960
Day's Range	13,510 - 14,450
52-Week Range	9,930 - 42,200
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations

Founded 2010

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 308430

Full Company Profile

Financial Performance

In 2025, CellBion's revenue was 1.95 billion, a decrease of -15.05% compared to the previous year's 2.29 billion. Losses were -7.57 billion, 4.23% more than in 2024.

Financial Statements